Durvalumab is a monoclonal antibody used in the treatment of cancer. It is specifically designed to target and inhibit the programmed death-ligand 1 (PD-L1) protein on the surface of cancer cells. By blocking this protein, durvalumab helps activate the immune system to attack and destroy cancer cells. It is commonly used in the treatment of certain types of lung cancer and bladder cancer.
